Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	360.04	56.86	67.21
Cash & Short-Term Investments	386.8	56.86	67.21
Cash Growth	434.91%	-15.40%	-
Prepaid Expenses	6.98	1.65	1.24
Other Current Assets	-	1.3	-
Total Current Assets	393.78	59.8	68.44
Property, Plant & Equipment	0.55	1.01	1.8
Long-Term Deferred Charges	-	1.39	-
Other Long-Term Assets	9.11	5.97	4.33
Total Assets	403.43	68.18	74.58
Accounts Payable	15.08	5.4	5.82
Accrued Expenses	28.53	17.01	19.44
Current Portion of Leases	0.38	0.56	0.72
Current Income Taxes Payable	-	0.3	-
Total Current Liabilities	44	23.26	25.97
Long-Term Debt	-	20.3	-
Long-Term Leases	-	0.26	0.81
Total Liabilities	44	43.82	26.78
Common Stock	0	0	0
Additional Paid-In Capital	694.16	4.64	1.03
Retained Earnings	-334.79	-230.4	-193.28
Comprehensive Income & Other	0.05	0.04	-0.04
Total Common Equity	359.44	-225.72	-192.29
Shareholders' Equity	359.44	24.37	47.8
Total Liabilities & Equity	403.43	68.18	74.58
Total Debt	0.38	21.11	1.53
Net Cash (Debt)	386.42	35.74	65.68
Net Cash Growth	652.56%	-45.58%	-
Net Cash Per Share	124.60	23.34	44.02
Filing Date Shares Outstanding	41.79	1.58	1.55
Total Common Shares Outstanding	41.78	1.58	1.55
Working Capital	349.78	36.55	42.48
Book Value Per Share	8.60	-143.15	-124.11
Tangible Book Value	359.44	-225.72	-192.29
Tangible Book Value Per Share	8.60	-143.15	-124.11

Source: S&P Capital IQ. Standard template. Financial Sources.